TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15898129

Group type: EXPERIMENTAL
Intervention: Nissen total fundoplication
Number of subjects: 163

Group type: COMPARATOR
Intervention: Anterior partial fundoplication
Number of subjects: 163
Study: 14564289

Group type: EXPERIMENTAL
Intervention: 7-mm tub preparation design
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 11-mm tub preparation design
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7-mm box preparation design
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 11-mm box preparation design
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7-mm pontic distance
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Box-shaped tooth preparation
Number of subjects: 80
Study: 10791875

Group type: EXPERIMENTAL
Intervention: Nucleoside analog therapies
Number of subjects: 0
Study: 8851904

Group type: EXPERIMENTAL
Intervention: Constant work rate tests at 40, 80, 120, 160, and 200 W
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regression analysis of VCO2 as a function of VO2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Comparison with ramp protocol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whole-body R at individual work rates
Number of subjects: 12
Study: 1363481

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Verapamil (increased dose from 240 to 600 mg)
Number of subjects: 362
Study: 6383687

Group type: EXPERIMENTAL
Intervention: Neomycin, 2 gm/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2879444

Group type: EXPERIMENTAL
Intervention: Nifedipine (50.0 ± 5.2 mg per day) + Atenolol (89.5 ± 25.7 mg per day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verapamil (460 ± 20 mg per day) + Enalapril (29.5 ± 5.0 mg per day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nifedipine (50.0 ± 5.2 mg per day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Verapamil (460 ± 20 mg per day)
Number of subjects: 24
Study: 30317101

Group type: EXPERIMENTAL
Intervention: O3PUFAs
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26314941

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 401
Study: 25089359

Group type: EXPERIMENTAL
Intervention: ACN-rich beverage (juice with 983.7 mg/l ACN)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ACN-rich beverage (smoothie with 840.9 mg/l ACN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ACN-rich beverage (juice and smoothie)
Number of subjects: 30
Study: 23588448

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (G2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 90
Study: 20156395

Group type: EXPERIMENTAL
Intervention: High identifiers expressing descriptively deviant opinions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-level self-definition as a moderator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-level self-investment as a moderator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Majority group members violating group norms
Number of subjects: 0
Study: 18717508

Group type: EXPERIMENTAL
Intervention: Oxymorphone immediate-release (IR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended-release (ER)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Titrated doses of oxymorphone ER
Number of subjects: 0
Study: 16365493

Group type: EXPERIMENTAL
Intervention: Buffered prilocaine (10 ml of prilocaine hydrochloride 2% buffered with 1 ml of sodium bicarbonate 8.4%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain prilocaine (10 ml of plain prilocaine hydrochloride 2% solution)
Number of subjects: 40
Study: 14644397

Group type: EXPERIMENTAL
Intervention: Avasimibe 750 mg QD
Number of subjects: 27

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg QD
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin 80 mg QD and avasimibe 750 mg QD
Number of subjects: 27
Study: 11021899

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. for 7 days (first phase)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m. for 2 weeks (second phase)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo for 2 weeks (second phase)
Number of subjects: 362
Study: 8626843

Group type: EXPERIMENTAL
Intervention: Testosterone transdermal system applied to the back for 24 hours
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Testosterone transdermal system applied to various sites (abdomen, back, chest, shin, thigh, upper arm) for 24 hours
Number of subjects: 34
Study: 1576117

Group type: EXPERIMENTAL
Intervention: D,L‐α‐tocopherol (vitamin E) 1,000 IU/day for 7 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: β‐carotene supplementation in smokers (n=23)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo group (n=23)
Number of subjects: 52
Study: 6374766

Group type: EXPERIMENTAL
Intervention: Endocervical prostaglandin E2 gel (0.5 mg in 2.5 ml)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Vaginal PGE2 tablet (2.0 mg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Endocervical prostaglandin E2 gel (0.5 mg) in women with Bishop score 0-2
Number of subjects: 121

Group type: COMPARATOR
Intervention: Vaginal PGE2 tablet (2.0 mg) in women with Bishop score 0-2
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo in women with Bishop score 0-2
Number of subjects: 121
Study: 31662396

Group type: EXPERIMENTAL
Intervention: Telemonitoring using Sense4Baby CTG devices, Microlife BP monitor, daily telephone calls with an obstetric healthcare professional, and weekly hospital visits.
Number of subjects: 416

Group type: COMPARATOR
Intervention: Traditional hospitalisation.
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 416

Group type: COMPARATOR
Intervention: Traditional hospitalisation
Number of subjects: 416
Study: 29370217

Group type: EXPERIMENTAL
Intervention: Hypobaric atmosphere (6380 ft)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Background noise (white noise at 70 dB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal conditions (no hypobaric or noise)
Number of subjects: 16
Study: 27519183

Group type: EXPERIMENTAL
Intervention: Vitamin E + placebo
Number of subjects: 35533

Group type: EXPERIMENTAL
Intervention: Selenium + placebo
Number of subjects: 35533

Group type: EXPERIMENTAL
Intervention: Vitamin E + selenium
Number of subjects: 35533

Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 35533
Study: 24512866

Group type: EXPERIMENTAL
Intervention: Implementation Intentions (II) technique with a leaflet attached to the test kit containing an 'if-then' condition and planning instructions.
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Standard care group (Control)
Number of subjects: 2200
Study: 22834725

Group type: EXPERIMENTAL
Intervention: Psychodynamic or psychoanalytically oriented treatments (PAT), up to 80 sessions in the first year, potentially extended to 240-300 sessions over two to three years.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), up to 60 sessions in the first year, potentially extended to 80 sessions focusing on maintenance and relapse prevention.
Number of subjects: 240
Study: 20713651

Group type: EXPERIMENTAL
Intervention: Low-fat high-carbohydrate (LFHC) diet
Number of subjects: 63

Group type: COMPARATOR
Intervention: High-fat low-carbohydrate (HFLC) diet
Number of subjects: 63
Study: 17545883

Group type: EXPERIMENTAL
Intervention: ECC+ (three sets of six reps at 40% 1RM concentric and 100% 1RM eccentric)
Number of subjects: 22

Group type: COMPARATOR
Intervention: TRAD (four sets of six reps at 52.5% 1RM)
Number of subjects: 22
Study: 15746299

Group type: EXPERIMENTAL
Intervention: 16 weeks of bicycle training (up to 45 min at 80% peak heart rate, 3-4 days/week)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Baseline (before training)
Number of subjects: 142
Study: 12006305

Group type: EXPERIMENTAL
Intervention: integrated care pathways management
Number of subjects: 76

Group type: COMPARATOR
Intervention: conventional multidisciplinary care
Number of subjects: 76
Study: 11120696

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8858222

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose 12-15 mmol/l)
Number of subjects: 8
Study: 1634643

Group type: EXPERIMENTAL
Intervention: Test preparation (20 mg isosorbide-5-mononitrate)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference preparation (20 mg isosorbide-5-mononitrate)
Number of subjects: 24
Study: 6519164

Group type: EXPERIMENTAL
Intervention: Piretanide (12 to 192 mg)
Number of subjects: 10
Study: 31087135

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Fluorouracil plus cisplatin (PF)
Number of subjects: 76
Study: 30373488

Group type: EXPERIMENTAL
Intervention: Patients who consented to participate in the RCT (n=713)
Number of subjects: 1338

Group type: COMPARATOR
Intervention: Patients who declined to participate in the RCT (n=625)
Number of subjects: 1338
Study: 28003206

Group type: EXPERIMENTAL
Intervention: Dietary zinc increase from 6 mg Zn/d to 10 mg Zn/d for 4 weeks
Number of subjects: 18
Study: 24870622

Group type: EXPERIMENTAL
Intervention: Deep breathing
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 87

Group type: COMPARATOR
Intervention: Un‐paced breathing
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 87
Study: 24232364

Group type: EXPERIMENTAL
Intervention: Assisted movement and muscle vibration combined with torque biofeedback
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Assisted movement and muscle vibration combined with EMG biofeedback
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Assisted movement and muscle vibration
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study: 21401921

Group type: EXPERIMENTAL
Intervention: Topiramate (up to 75 mg per day) with psychotherapy (n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Psychotherapy alone (n = 60)
Number of subjects: 90
Study: 18492379

Group type: EXPERIMENTAL
Intervention: diclofenac sodium suppository 100 mg (Voltarol) at the end of oocyte retrieval
Number of subjects: 381

Group type: COMPARATOR
Intervention: nothing (control group)
Number of subjects: 381
Study: 17176187

Group type: EXPERIMENTAL
Intervention: Multidimensional family therapy with family-focused techniques
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Multidimensional family therapy with adolescent-focused techniques
Number of subjects: 63
Study: 14580004

Group type: EXPERIMENTAL
Intervention: RMT50 (50 microg/actuation)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: RMT100 (100 microg/actuation)
Number of subjects: 41

Group type: COMPARATOR
Intervention: MDI100 (100 microg/actuation)
Number of subjects: 41
Study: 10883827

Group type: EXPERIMENTAL
Intervention: Antibiotic prescribed according to culture and sensitivity (Group A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Broad-spectrum antimicrobial (co-trimoxazole) prescribed blindly (Group B)
Number of subjects: 110
Study: 9369053

Group type: EXPERIMENTAL
Intervention: Lidocaine containing adhesive tape (LT) applied for 6 hours
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Lidocaine containing adhesive tape (LT) applied for 8 hours
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Lidocaine containing adhesive tape (LT) applied for longer than 3 hours
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Lidocaine containing adhesive tape (LT) applied for 12 hours
Number of subjects: 617

Group type: COMPARATOR
Intervention: Control group (no lidocaine tape)
Number of subjects: 617
Study: 8404800

Group type: EXPERIMENTAL
Intervention: Experimental group received a compliment and a self-descriptive questionnaire before receiving a mailed brochure about the bone-marrow registry.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received only the mailed brochure.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mailing group (control).
Number of subjects: 0
Study: 3535860

Group type: EXPERIMENTAL
Intervention: Topical application of lignocaine-prilocaine cream (EMLA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29705459

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 26522233

Group type: EXPERIMENTAL
Intervention: Gluten-free bread (GFB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Added gluten content bread (AGCB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal gluten content bread (NGCB)
Number of subjects: 12
Study: 24685369

Group type: EXPERIMENTAL
Intervention: Ultra‐MIS (1mm incision)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mini‐OCTR (2 cm incision)
Number of subjects: 40
Study: 24201696

Group type: EXPERIMENTAL
Intervention: 4 mg perindopril daily for 20 weeks
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Exercise training + ACEi
Number of subjects: 170

Group type: COMPARATOR
Intervention: Exercise training only
Number of subjects: 170
Study: 20220293

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone undecanoate (im TU)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (oral TU)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Transdermal placebo gel (P)
Number of subjects: 52
Study: 17575569

Group type: EXPERIMENTAL
Intervention: Communication skills training program (6 workshops of 3 hours each following a 2.5-day basic training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 0
Study: 16402614

Group type: EXPERIMENTAL
Intervention: Hidden Markov models (HMMs) with five to ten hidden states for blood pressure variability classification
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hidden Markov models (HMMs) with fifteen hidden states for RR-based classification
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pregnancy disorders (preeclampsia and pregnancy-induced hypertension)
Number of subjects: 90
Study: 14721993

Group type: EXPERIMENTAL
Intervention: Temporary epicardial pacing wires (PWs)
Number of subjects: 197

Group type: COMPARATOR
Intervention: No pacing wires (PWs)
Number of subjects: 197
Study: 11016387

Group type: EXPERIMENTAL
Intervention: Cryoablation therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intercostal application of local anesthetic agents (Control)
Number of subjects: 57
Study: 8879616

Group type: EXPERIMENTAL
Intervention: Purged PBPC (75 micrograms/ml of ether lipid for 4 h at 37 degrees C)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-purged PBPC
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Purged PBPC
Number of subjects: 37
Study: 7868698

Group type: EXPERIMENTAL
Intervention: Inattentive (I)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Inattentive and Impulsive (II)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Hyperactive and Impulsive (HII)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 116
Study: 3340909

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 16

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 16
Study: 29978597

Group type: EXPERIMENTAL
Intervention: 2% taurolidine
Number of subjects: 105

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 105
Study: 27980016

Group type: EXPERIMENTAL
Intervention: Higher temperature
Number of subjects: 981

Group type: COMPARATOR
Intervention: Precipitation, humidity, wind speed, wind gust, wind direction, air pressure
Number of subjects: 981
Study: 28500216

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Higher glycated hemoglobin at year 8
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Cumulative metformin exposure
Number of subjects: 2280
Study: 23725995

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with implantable cardioverter defibrillator (ICD), n = 132
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with ICD, n = 132
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (ICD-only), n = 87
Number of subjects: 132
Study: 21418447

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (cereal-lentil mixture providing 930 kcal and multivitamin micronutrient supplement)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 103
Study: 19655825

Group type: EXPERIMENTAL
Intervention: OAC plus atorvastatin 40 mg/day and ezetimibe 10 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 18247250

Group type: EXPERIMENTAL
Intervention: Treatment Implementation (TI) methods in a rehabilitation team‐training intervention
Number of subjects: 29
Study: 14760792

Group type: EXPERIMENTAL
Intervention: Tacrolimus 3 mg/day
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Tacrolimus 1.5 mg/day
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 11772141

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorouracil plus leucovorin
Number of subjects: 0
Study: 9661016

Group type: EXPERIMENTAL
Intervention: DU-6859a 50 mg b.i.d. for 5 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DU-6859a 100 mg b.i.d. for 5 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Theophylline (TP) 200 mg b.i.d. for 9 days
Number of subjects: 6
Study: 7595905

Group type: EXPERIMENTAL
Intervention: Losartan monotherapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Losartan-HCTZ combination therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Losartan (both monotherapy and combination therapy)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 12
Study: 2204855

Group type: COMPARATOR
Intervention: Nd:YAG laser alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Argon laser pretreatment followed by Nd:YAG laser
Number of subjects: 12
Study: 645143

Group type: EXPERIMENTAL
Intervention: haemiton compositum
Number of subjects: 14
Study: 31612482

Group type: EXPERIMENTAL
Intervention: Erenumab 28 mg
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 475

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study: 29200836

Group type: EXPERIMENTAL
Intervention: Computerized cognitive stimulation (CCS) program
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Computerized cognitive engagement (CCE) program
Number of subjects: 19
Study: 25596848

Group type: EXPERIMENTAL
Intervention: Workplace physical exercise (WORK) performed during working hours for 5×10 minutes per week
Number of subjects: 200

Group type: COMPARATOR
Intervention: Home-based physical exercise (HOME) performed during leisure time for 5×10 minutes per week
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Workplace physical exercise (WORK)
Number of subjects: 200
Study: 23130781

Group type: EXPERIMENTAL
Intervention: CRT plus defibrillator device implantation
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: AF history
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Recurrent or new atrial arrhythmias
Number of subjects: 406
Study: 21514032

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone once daily for 14 days after insemination
Number of subjects: 71

Group type: COMPARATOR
Intervention: No progesterone (unsupported cycles)
Number of subjects: 71
Study: 18444848

Group type: EXPERIMENTAL
Intervention: Daptomycin (4 mg/kg) once daily for 5-14 days
Number of subjects: 834

Group type: COMPARATOR
Intervention: Ceftriaxone (2 g) once daily for 5-14 days
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Daptomycin (4 mg/kg) once daily for 5-14 days with prior effective therapy
Number of subjects: 834

Group type: COMPARATOR
Intervention: Ceftriaxone (2 g) once daily for 5-14 days with prior effective therapy
Number of subjects: 834
Study: 16596465

Group type: EXPERIMENTAL
Intervention: Low dose risperidone
Number of subjects: 40
Study: 12691439

Group type: EXPERIMENTAL
Intervention: Applanation resonator sensor (ARS) for measuring IOP
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Redesigned spherical contact surface of the sensor probe
Number of subjects: 180
Study: 11094588

Group type: EXPERIMENTAL
Intervention: Rapacuronium 2.0 mg kg-1
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Rapacuronium 2.5 mg kg-1
Number of subjects: 602

Group type: COMPARATOR
Intervention: Succinylcholine 1.0 mg kg-1
Number of subjects: 602

Group type: COMPARATOR
Intervention: Rapacuronium 2.0 mg kg-1 vs Succinylcholine
Number of subjects: 602

Group type: COMPARATOR
Intervention: Rapacuronium 2.5 mg kg-1 vs Succinylcholine
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Rapacuronium (both doses)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 602
Study: 1723288

Group type: EXPERIMENTAL
Intervention: Early consolidation therapy with 6 courses of CVP (cyclophosphamide, vincristine, prednisone) given monthly
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with cyclophosphamide and prednisone given every 6 weeks for 2 years
Number of subjects: 81

Group type: COMPARATOR
Intervention: No further treatment (observation)
Number of subjects: 81
Study: 7468581

Group type: EXPERIMENTAL
Intervention: Four doses of human diploid cell strains rabies vaccine (HDCV) administered in three days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four doses of human diploid cell strains rabies vaccine (HDCV) administered in 14 days
Number of subjects: 0